IRIS
BOLZONI, Marina
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 3.489
AS - Asia 3.290
EU - Europa 2.374
SA - Sud America 424
AF - Africa 166
Continente sconosciuto - Info sul continente non disponibili 9
Totale 9.752
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 3.389
SG - Singapore 1.269
CN - Cina 1.217
SE - Svezia 499
IE - Irlanda 434
FI - Finlandia 428
BR - Brasile 346
IT - Italia 258
DE - Germania 249
HK - Hong Kong 239
TR - Turchia 201
VN - Vietnam 165
NL - Olanda 105
ZA - Sudafrica 97
CA - Canada 79
UA - Ucraina 61
GB - Regno Unito 58
FR - Francia 49
IN - India 49
RU - Federazione Russa 40
CI - Costa d'Avorio 39
AT - Austria 36
AR - Argentina 35
BE - Belgio 30
BD - Bangladesh 28
RO - Romania 28
JP - Giappone 22
PL - Polonia 22
CZ - Repubblica Ceca 18
ES - Italia 18
LT - Lituania 15
EC - Ecuador 11
IQ - Iraq 11
MX - Messico 11
UZ - Uzbekistan 10
CO - Colombia 9
PK - Pakistan 9
EU - Europa 8
KR - Corea 8
KZ - Kazakistan 8
AE - Emirati Arabi Uniti 7
VE - Venezuela 6
MA - Marocco 5
PY - Paraguay 5
SN - Senegal 5
BG - Bulgaria 4
ID - Indonesia 4
KE - Kenya 4
SA - Arabia Saudita 4
UY - Uruguay 4
BO - Bolivia 3
CH - Svizzera 3
CM - Camerun 3
IL - Israele 3
KH - Cambogia 3
MY - Malesia 3
OM - Oman 3
PE - Perù 3
PH - Filippine 3
QA - Qatar 3
TN - Tunisia 3
TW - Taiwan 3
AO - Angola 2
AZ - Azerbaigian 2
CL - Cile 2
CY - Cipro 2
DK - Danimarca 2
DO - Repubblica Dominicana 2
DZ - Algeria 2
EE - Estonia 2
EG - Egitto 2
HR - Croazia 2
HU - Ungheria 2
IR - Iran 2
JM - Giamaica 2
JO - Giordania 2
MD - Moldavia 2
PA - Panama 2
PT - Portogallo 2
SM - San Marino 2
SY - Repubblica araba siriana 2
AL - Albania 1
AM - Armenia 1
BB - Barbados 1
BW - Botswana 1
BY - Bielorussia 1
CG - Congo 1
CR - Costa Rica 1
GA - Gabon 1
GD - Grenada 1
GT - Guatemala 1
KG - Kirghizistan 1
KW - Kuwait 1
LB - Libano 1
LK - Sri Lanka 1
LU - Lussemburgo 1
LV - Lettonia 1
NG - Nigeria 1
NP - Nepal 1
PS - Palestinian Territory 1
Totale 9.749
Salva come PNG Salva come JPEG
Città #
Singapore 620
Dublin 432
Chandler 421
Ashburn 415
Beijing 332
Santa Clara 296
Hong Kong 234
Dallas 195
Izmir 165
Dearborn 157
Parma 141
Nanjing 138
Jacksonville 134
Ann Arbor 106
New York 103
Boardman 102
Johannesburg 91
Los Angeles 87
Princeton 86
Shanghai 86
Munich 76
Ho Chi Minh City 68
San Mateo 59
Shenyang 59
Kunming 57
Toronto 49
Düsseldorf 42
Nanchang 42
Hebei 41
Abidjan 39
Hefei 38
Helsinki 38
Wilmington 37
Columbus 33
Jinan 33
São Paulo 31
Vienna 31
Brussels 30
Tianjin 29
Hanoi 28
Jiaxing 28
Moscow 28
Kocaeli 27
Changsha 26
Buffalo 25
Turku 24
Marseille 23
Focsani 22
Tokyo 22
Warsaw 20
Des Moines 19
Seattle 18
Bremen 17
Guangzhou 16
Brno 15
Chicago 15
Houston 15
Milan 15
Montreal 15
Stockholm 14
Hangzhou 13
Norwalk 13
Orem 13
Poplar 13
Brooklyn 12
Zhengzhou 12
Atlanta 11
Boston 11
Denver 11
London 11
Pune 11
Council Bluffs 10
Redmond 10
Chengdu 9
Chennai 9
Chongqing 9
Frankfurt am Main 9
Tashkent 9
The Dalles 9
Wuhan 9
Ankara 8
Belo Horizonte 8
Fuzhou 8
Hải Dương 8
Mestre 8
Seoul 8
Haiphong 7
Palermo 7
Philadelphia 7
Phoenix 7
Rio de Janeiro 7
Rome 7
San Francisco 7
Taizhou 7
Woodbridge 7
Ahmedabad 6
Amsterdam 6
Dubai 6
Guarulhos 6
Ninh Bình 6
Totale 5.960
Salva come PNG Salva come JPEG
Nome #
Are the Myeloma bone microevironment cells tumoral or not? 195
Ammonium Production and Glutamine-Addiction of Myeloma Cells: New Attractive Targets in Multiple Myeloma 193
Dependence on glutamine uptake and glutamine addiction characterize myeloma cells: a new attractive target 181
Bone marrow CX3CL1/Fractalkine is a new player of the pro-angiogenic microenvironment in multiple myeloma patients 179
Osteolytic lesions, cytogenetic features and bone marrow levels of cytokines and chemokines in multiple myeloma patients: Role of chemokine (C-C motif) ligand 20 168
HOXB7 expression by myeloma cells regulates their pro-angiogenic properties in multiple myeloma patients 165
Hypoxia and Hypoxia Inducible Factor (HIF)-1{alpha} in Multiple Myeloma: Effect on the Pro-Angiogenic Signature of Myeloma Cells and the Bone Marrow Microenvironment 161
CC-4047 (Pomalidomide) inhibits multiple myeloma-induced osteoclast formation targeting RANKL in the bone marrow microenvironment 159
Hypoxia-Inducible Factor (HIF)-1 alpha Inhibitionin Myeloma Cells Significantly Increases the Anti-Myeloma Effect of Lenalidomide in Vivo 158
Activation of non-canonical wnt pathway in human mesenchymal cells affects osteogenic differentiation: a potential target in Multiple Myeloma microenvironment 156
HOXB7 is a key gene involved in Myeloma cell growth and Myeloma-induced angiogenesis in Multiple Myeloma patients 152
Hypoxia and hypoxia inducible factor (HIF)-1α in Multiple Myeloma patients: role in the angiogenic switch 148
Expression of CD38 in myeloma bone niche: A rational basis for the use of anti-CD38 immunotherapy to inhibit osteoclast formation 147
The Immunomodulatory drugs Lenalidomide and Pomalidomide inhibit multiple myeloma-induced osteoclast formation and RANKL/OPG ratio in myeloma microenvironment targeting the expression of adhesion molecules 146
Oxygen tension in the bone marrow (BM) of patients with malignant and indolent monoclonal gammopathy: role of hypoxia and hypoxia-inducible factor (HIF)-1{alpha} in the regulation of gene expression and pro-angiogenic profiles of CD138+ cells 143
EXPRESSION OF CD38 AND ECTOENZYMES OF THE ADENOSINERGIC PATHWAYS IN MYELOMA BONE NICHE: A RATIONAL BASIS FOR THE USE OF DARATUMUMAB TO TARGET OSTEOCLAST FORMATION IN MULTIPLE MYELOMA 141
Bortezomib improves bone integrity in multiple myeloma patients by blocking osteocyte death and autophagy 140
Myeloma cells inhibit non-canonical wnt co-receptor ror2 expression in human bone marrow osteoprogenitor cells: effect of wnt5a/ror2 pathway activation on the osteogenic differentiation impairment induced by myeloma cells 139
HOXB7 is critically involved in Multiple Myeloma-induced angiogenic switch 138
The homeobox gene HOXB7 regulates the production of pro-angiogenic molecole by myeloma cells and it is a target in myeloma-induced angiogenesis 137
Myeloma cells inhibit the non-canonical wnt co-receptor ror2 in human mesenchymal/osteoprogenitor cells: effect of wnt5a/ror2 pathway activation on mm-induced impairment of the osteogenic differentiation process 136
Glutamine dependence and PIK3CA mutations in colon-rectal cancer cells: ATF4 enters the stage 135
The IMID CC-4047 (Pomalidomide) inhibits myeloma-induced osteoclast formation 134
LENALIDOMIDE INCREASES HUMAN DENDRITIC CELL MATURATION MODULATING BOTH MONOCYTE DIFFERENTIATION AND MESENCHYMAL STROMAL CELL INHIBITORY PROPERTIES 134
Use of traffic crash as a risk assessment scale in hospitalized seniors: A perspective observational study 134
Cutaneous localization in multiple myeloma in the context of bortezomib-based treatment: how do myeloma cells escape from the bone marrow to the skin? 132
DEPENDENCE ON GLUTAMINE UPTAKE OF MYELOMA CELLS DELINEATES A NEW ATTRACTIVE THERAPEUTIC STRATEGY 131
Galectin-1 suppression delineates a new strategy to inhibit myeloma-induced angiogenesis and tumoral growth in vivo 130
In vitro and In vivo evidences of osteocytes involvement in myeloma-induced osteolysis 129
Galectin-1 Is Highly Expressed By Myeloma Cells and the Bone Marrow Microenvironment and Its Suppression Delineates a New Therapeutic in Vitro and in Vivo Strategy in Multiple Myeloma 128
Expression Profile of CD38 and Related Ectoenzymes in Myeloma Bone Niche: A Rational Basis for the Use of Daratumumab to Inhibit Osteoclast Formation and Activity 128
Generation and Characterization of Microvesicles after Daratumumab Interaction with Myeloma Cells 126
IL21R expressing CD14+CD16+ monocytes expand in multiple myeloma patients leading to increased osteoclasts 126
The anti-tumoral effect of lenalidomide is increased in vivo by hypoxia-inducible factor (HIF)-1α inhibition in myeloma cells 124
Bone marrow CD14+ cells show different transcriptional profiles in Multiple Myeloma (MM) as compared to smoldering MM and MGUS: overexpression of IL21R and its involvement in osteoclastogenesis 123
Lenalidomide increases human dendritic cell maturation in multiple myeloma patients targeting monocyte differentiation and modulating mesenchymal stromal cell inhibitory properties 122
Non canonical wnt signal pathway (Wnt5a/ror2) activation stimulates the osteogenic differentiation process of bone mesenchymal cells being a potential target in multiple myeloma bone disease 121
Bone marrow monocyte / macrophage derived activin a mediates the osteoclastogenic effects of IL-3 in myeloma 121
The osteoblastic niche in the context of multiple myeloma 119
Increased osteocyte apoptosis in Multiple Myeloma patients: a potential role in bone remodeling alterations related to osteolytic bone lesions 119
Angiogenesis and multiple myeloma 118
Modulation of non canonical wnt5a/ror2 signaling pathway in human mesenchymal cells increases osteogenic differentiation counterbalancing the effect of myeloma cells 117
Increased osteocyte death in multiple myeloma patients: role in myeloma-induced osteoclast formation 116
Possible targets to treat myeloma-related osteoclastogenesis 115
Bone osteoblastic and mesenchymal stromal cells lack primarily tumoral features in multiple myeloma patients 114
The anti-myeloma effect of Lenalidomide is increased by hypoxia-inducible factor (HIF)-1a inhibition in multiple myeloma cells both in vitro and in vivo 113
The link between bone microenvironment and immune cells in multiple myeloma: Emerging role of CD38 113
Oncolytic Virotherapy in Multiple Myeloma: A Possible Alternative Role of Bovine Viruses 110
Lenalidomide Increases Human Dendritic Cell Maturation in Multiple Myeloma Modulating Both Monocyte Differentiation and Mesenchymal Stromal Cell Inhibitory Properties through Ikaros and Casein Kinase 1 Degradation, Respectively 105
The activation of wnt5a-mediated non canonical wnt signaling in human bone marrow osteoprogenitor cells increases osteoblastogenesis and counterbalances the inhibitory effect of myeloma cells on ror2/fzd5 expression 104
Bone marrow monocyte-/macrophage-derived activin A mediates the osteoclastogenic effect of IL-3 in multiple myeloma 104
Il mieloma multiplo nell'era dei nuovi farmaci. Patogenesi 102
Trascriptome Analysis of Bone Marrow CD14+ Monocytes Revealed Differential Expression Profiles in Symptomatic Multiple Myeloma (MM) Compared to Smoldering MM and Monoclonal Gammopathy of Undetermined Significance 102
Hypoxia-inducible factor (HIF)-1 is a therapeutic target in myeloma-induced angiogenesis and bone destruction in vitro and in vivo 100
Unraveling the contribution of ectoenzymes to myeloma life and survival in the bone marrow niche 99
Proteasome Inhibitors Block Myeloma-Induced Osteocyte Death in Vitro and in Vivo in Multiple Myeloma Patients 96
Distinct transcriptional profiles characterize bone microenvironment mesenchymal cells rather than osteoblasts in relationship with Multiple Myeloma bone disease 95
Relationship between bone imaging features and bone marrow cytokine and chemokine profiles in patients with monoclonal gammopathy 93
Hypoxia-Inducible Factor (HIF)-1a Is A Therapeutic Target in Myeloma-Induced Angiogenesis and Bone Destruction in Vivo 93
Overexpression of HOXB7 and homeobox genes characterizes multiple myeloma patients lacking the major primary immunoglobulin heavy chain locus translocations 92
Bisphosphonates in multiple myeloma: Preclinical and clinical data. 92
Overexpression of Pro-Osteoclastogenic Cytokine Receptors and Chemokines By Bone Marrow CD14(+) Monocytes of Multiple Myeloma (MM) Patients As Compared to Smoldering MM (SMM) and Monoclonal Gammopathy of Uncertain Significance (MGUS): Role of Interleukin(IL)-21 Receptor/IL-21 Axis in MM-Induced Osteoclastogenesis 89
Transcriptional and proteomic profiles of bone marrow CD14+ cells in multiple myeloma (MM) compared to smoldering MM and MGUS: overexpression of Interleukin (IL)-21 receptor and its involvement in MM-induced osteoclastogenesis 87
Relationship between skeletal involvement, cytogenetic features and bone marrow profiles of cytokines and chemokines in patients with monoclonal gammopathy 86
The potential of inhibiting glutamine uptake as a therapeutic target for multiple myeloma 83
The proapoptotic effect of zoledronic acid is independent of either the bone microenvironment or the intrinsic resistance to bortezomib of myeloma cells and is enhanced by the combination with arsenic trioxide 83
Hypoxia-inducible factor (HIF)-1α suppression in myeloma cells blocks tumoral growth in vivo inhibiting angiogenesis and bone destruction 82
The Proteasome Inhibitor Bortezomib Maintains Osteocyte Viability in Multiple Myeloma Patients by Reducing Both Apoptosis and Autophagy: A New Function for Proteasome Inhibitors 82
Interleukin-3 induces activin A in bone marrow monocytes: role in multiple myeloma patients 81
High ASCT2 activity as a marker of extracellular glutamine dependence in ammoniagenic multiple myeloma cell lines 81
Assessing satisfaction in simulation among nursing students: psychometric properties of the Satisfaction with Simulation Experience - Italian Version scale 80
Relationship between presence of osteolytic lesions, cytogenetic features and bone marrow levels of cytokines and chemokines in multiple myeloma patients: role of chemokine (C-C motif) ligand 20 80
Ectoenzymes and Their Products As Communicators in the Human Myeloma Niche 79
The Myeloma Cells Escape from Bone Marrow to Skin Extramedullary Localization upon Bortezomib Resistance: Role of CXCR4 79
IL3 Induces Osteoclastogenesis In Vivo and Is Modulated By Bone Marrow Monocyte / Macrophage Derived Activin A 78
Immunomodulatory drugs lenalidomide and pomalidomide inhibit multiple myeloma-induced osteoclast formation and the RANKL/OPG ratio in the myeloma microenvironment targeting the expression of adhesion molecules 78
NAD⁺-Metabolizing Ectoenzymes in Remodeling Tumor-Host Interactions: The Human Myeloma Model 78
Validity and reliability of the Italian version of painad for postoperative pain assessment in geriatric patients with proximal femur fractures 76
Low bone marrow oxygen tension and hypoxia-inducible factor-1α overexpression characterize patients with multiple myeloma: role on the transcriptional and proangiogenic profiles of CD138(+) cells 76
Myeloma-Induced osteocyte death was blunted by proteasome inhibitors through the modulation of autophagy 76
Proteasome inhibitors modulate osteocyte death and autophagy in multiple myeloma 76
Hypoxia-Inducible Factor (HIF)-1α Is a Therapeutic Target in Myeloma-Induced Angiogenesis 72
New insights into osteogenic and chondrogenic differentiation of human bone marrow mesenchymal stem cells and their potential clinical applications for bone regeneration in pediatric orthopaedics 70
Mechanism of action of bortezomib and the new proteasome inhibitors on myeloma cells and the bone microenvironment: Impact on myeloma-induced alterations of bone remodeling 66
Microvesicles released from multiple myeloma cells are equipped with ectoenzymes belonging to canonical and non-canonical adenosinergic pathways and produce adenosine from ATP and NAD+ 62
Myeloma and osteoclast relationship 56
Evaluation of a New Automated Mono-Test for the Detection of Aspergillus Galactomannan: Comparison of Aspergillus Galactomannan Ag VirCLIA® Mono-Test with PlateliaTM Aspergillus Ag ELISA Assay 55
Role of osteocytes in myeloma bone disease: Anti-sclerostin antibody as new therapeutic strategy 50
Totale 9.932
Salva come PNG Salva come JPEG
Categoria #
all - tutte 34.823
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 34.823
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021231 0 0 0 0 0 9 12 4 112 37 36 21
2021/2022402 7 1 8 42 12 8 36 37 29 40 32 150
2022/20231.687 199 193 124 109 131 183 47 107 519 24 41 10
2023/2024590 24 52 11 15 39 185 50 25 12 37 37 103
2024/20252.053 46 95 109 170 226 227 71 67 263 188 185 406
2025/20262.571 410 369 550 456 646 140 0 0 0 0 0 0
Totale 9.932